HIV, which affects more than 38 million people globally, is a fast-mutating virus. This has continued to cause fears in the minds of people all over the world, at least, before COVID-19.
An HIV vaccine are been developed by non-profit organisation, IAVI and Scripps Research which said the new method was successful in stimulating the production of rare immune cells that generate antibodies.
“The vaccine showed success in stimulating the production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine,” the two organisations said in a statement.
“This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well,” said William Schief, a professor and immunologist at Scripps Research and executive director of vaccine design at IAVI’s Neutralizing Antibody Center (NAC).
According to moneycontrol.com, IAVI and Scripps Research will partner with biotechnology company Moderna to develop and test an mRNA-based vaccine.
Moderna is the U.S based company that developed the Covid vaccine with 94.1 percent efficacy.
